TFSA Investors: This Undervalued Gem Could Turn $6,000 Into $25,000

Here’s why TFSA investors can hold undervalued growth stocks such as Verano in their portfolios right now.

Money growing in soil , Business success concept.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

The Tax-Free Savings Account, or TFSA, is a popular registered account among Canadians. You can hold different types of investments in your TFSA that include stocks, bonds, and exchange-traded funds.

Any withdrawal from the TFSA is exempt from Canada Revenue Agency taxes, making it ideal for growth investors. It makes sense to hold a portfolio of quality growth stocks in your TFSA and benefit from exponential gains over time. Further, the ongoing selloff allows you to buy quality stocks at massive discounts.

The maximum cumulative contribution room that’s available for a TFSA investor stands at $81,500. For 2022, the maximum TFSA contribution room is $6,000. Let’s take a look at one such undervalued stock that can turn a $6,000 investment into $25,000 by 2030.

Verano Holdings should be part of your TFSA in 2022

Valued at US$2.3 billion by market cap, Verano Holdings ended 2021 with US$737.85 million in sales. Verano is a vertically integrated, multi-state cannabis operator in the United States. It produces a wide suite of premium brands that include Verano, Avexia, and Encore.

It has a presence in 15 states in the U.S. with active operations in 13 states. The company has 13 cultivation and processing facilities with one million square feet of cultivation capacity.

In Q1 of 2022, Verano increased revenue by 67% year over year to US$202 million. Its gross profit stood at US$100 million, accounting for 49% of sales. In the year-ago period, its gross profit stood at US$54 million. It’s selling, general, and administrative expenses were US$80 million, which was 40% of sales.

Verano ended Q1 with an adjusted EBITDA of US$81 million, accounting for 40% of sales. Its cash flow from operations and free cash flow for the March quarter were US$53 million and US$6 million, respectively.

Earlier this year, Verano entered an agreement to acquire Goodness Growth Holdings to establish a foundation in high-growth markets such as New York, New Mexico, and Minnesota. It also drew US$100 million under a senior secured credit agreement with an option of increasing the amount to US$175 million.

Verano increased its retail footprint by opening two dispensaries in Florida and another one in West Virginia.

What’s next for Verano stock and investors?

Verano ended Q1 with US$340 million in current assets and US$140 million in cash, providing it with enough flexibility to reinvest in growth opportunities. During Verano’s Q1 earnings press release, its Founder and CEO, George Archos stated, “We remain focused on execution, evidenced by our continued retail footprint expansion, where we added seven locations in the first quarter, including our first Zen Leaf dispensary in West Virginia.”

Additionally, the company’s sale of adult-use cannabis began in New Jersey, which should be a key revenue driver for Verano in 2022. Verano is well positioned to capitalize on similar opportunities in the near term.

In Q2 of 2022, Verano will add Zen Leaf Neptune as an adult-use dispensary and will invest in its business through several cultivation, construction, and expansion projects.

Verano is on track to report sales of US$1.24 billion in 2022, valuing the company at less than two times forward sales. Its forward price-to-earnings multiple is also attractive at 18, making it a top pick for value investors.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Aditya Raghunath has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »